Skip to main content
. 2006 Jul 19;2006(3):CD001694. doi: 10.1002/14651858.CD001694.pub2

Robbins 1993.

Methods Blinding of randomization: yes 
 Blinding of intervention: yes 
 Complete follow up: yes 
 Blinding of outcome: yes 
 Randomized clinical trial, parallel design 
 No washout period documented
Participants Number of patients entered into the study: n=10 
 Mechanical ventilation 
 Inclusion criteria: BPD 
 Of 10 patients, five were allocated to each group. There was no significant difference between the two groups in any of the variables analyzed. Average birth weight was similar in furosemide‐treated patients and in those on placebo, 671±136 g and 786±242, g respectively. Mean gestational age was, respectively, 26.2±1.8 and 26.2±1.3 weeks, mean weight at entry 850±179 and 944±293 g, mean postnatal age 31±13 and 24±7 days, and postconceptional age 30.6±2.6 and 29.6±1.6 weeks, respectively. Peak inspiratory pressure was similar in both groups (20.2±1.8 vs 19.6±1.8 cm H2O), so were positive end expiratory pressure (5.2±1.1 and 5.0±1.0 cm) and FiO2 (0.41±0.25 and 0.41±20).
Interventions Aerosolized furosemide vs placebo 
 Patients were randomly allocated to receive either aerosolized furosemide 1 mg/kg in 2 ml normal saline or placebo (normal saline) for seven days. The interval of administration is not stated in the abstract.
Outcomes Main outcome: pulmonary mechanics. 
 There was no significant difference in compliance or in resistance between the two groups.
Notes Abstract form only; no information available about frequency of administration, type of nebulizer, flow, other medications. 
 Pulmonary function tests (dynamic compliance and resistance) were obtained 15 minutes before aerosol, 30 minutes after the first dose and again on day 7 before the aerosol.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence generation? Unclear risk Blinding of randomization: yes
Allocation concealment? Low risk Blinding of randomization: yes
Blinding? 
 All outcomes Low risk Blinding of intervention: yes 
 
 Blinding of outcome: yes
Incomplete outcome data addressed? 
 All outcomes Low risk Complete follow‐up: yes
Free of selective reporting? Unclear risk Abstract form only
Free of other bias? Unclear risk Randomized clinical trial, parallel design 
 No washout period documented

± always precedes SD